1. OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study. (12th June 2018) Authors: Wallace, D.J.; Furie, R.A.; Tanaka, Y.; Kalunian, K.C.; Mosca, M.; Petri, M.A.; Dorner, T.; Cardiel, M.H.; Bruce, I.N.; Gomez, E.; Carmack, T.; Janes, J.M.; Linnik, M.D.; Silk, M.; Hoffman, R. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus. (10th June 2014) Authors: Furie, R.A.; Petri, M.; Gordon, C.; Strand, V.; Galateanu, C.; Bongardt, S.; Koetse, W.; Wallace, D.J. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0387 Effects of Blisibimod, An Inhibitor of B Cell Activating Factor, On Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus. (9th June 2015) Authors: Petri, M.; Martin, R.S.; Hislop, C.; Scheinberg, M.A.; Furie, R.A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 336 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗